Military to Offer Testosterone Therapy

Defense Secretary Pete Hegseth has ordered annual testosterone screening for U.S. service members age 30 and older, and the policy is already stirring questions about readiness, medicine, and control inside the ranks.

Quick Take

Hegseth said the screening will be part of annual health checks for troops 30 and older.
Service members with low testosterone will be offered testosterone replacement therapy, but treatment is voluntary.
Doctors quoted in reporting said routine testing of asymptomatic troops lacks solid evidence.
The move fits Hegseth’s wider push for tougher physical standards and a harder military culture.

What Hegseth Announced

Hegseth said the Pentagon will add testosterone deficiency screening to periodic health assessments for service members 30 and older. Reporting says he framed the plan as a way to restore natural ability, improve readiness, and support long-term health. He also said younger troops may be able to opt in, while those who test low would be offered treatment without being forced to take it.

The announcement matters because it turns a hormone linked to aging and male health into a military policy issue. Reuters reported that Hegseth said the goal is to keep troops at their best, while doctors warned that the evidence for universal screening in healthy adults is thin. The policy was presented as routine care, but it also places a sensitive medical question inside a chain of command built on obedience.

Why Supporters Say It Makes Sense

Supporters of the plan point to age-related hormone decline and the physical demands of service. Hegseth said testosterone often drops as people get older, and reporting quoted him saying the program is not meant to create artificial enhancement. The underlying argument is simple: if low testosterone can affect energy, muscle mass, and stamina, then finding it early may help troops stay fit for duty and avoid problems later.

That logic fits a broader push inside the Pentagon to stress raw physical readiness. Reporting from local and national outlets tied the testosterone program to tougher fitness tests and daily training goals already favored by Hegseth. In that frame, the screening is not just about health care. It is also about building a force that looks stronger, trains harder, and matches the image of the “warfighter” the administration wants to project.

Why Doctors Are Skeptical

Several doctors quoted by Reuters said routine screening of all service members over 30 is not backed by strong evidence. The American Urological Association and the Endocrine Society recommend treatment for men who have both low levels and symptoms, not blanket testing of people who feel fine. Those concerns matter because testosterone therapy can bring risks, including fertility problems and other side effects if it is used when it is not clearly needed.

Doctors Warn Hegseth Against Military Testosterone Tests

“Defense Sec. Pete Hegseth this week ordered annual testosterone-deficiency screening for active-duty and reserve service members age 30 and older, which he says will help to maintain military readiness.

“But many…
1/2

— ˶˃ News Reader Cat 📰🗞️NO DMs˂˶ (@typocatCAv2) July 18, 2026

The policy also leaves important questions unanswered. Reporting says the Pentagon has not clearly explained what testosterone level counts as low enough for action, whether women will be screened the same way, or how consent will work for testing itself. Those gaps make the program look unfinished, even after the headline announcement. Until the military releases a formal directive, the public is left with a broad promise and few hard details.

What This Says About the Military Right Now

The testosterone plan shows how military health policy is moving toward performance management, not just disease care. That can appeal to people who want a stronger force and think the federal government has been too soft, too slow, or too political. At the same time, critics on the left and right can see the same problem: a powerful institution making a medical move before it has clearly shown the science, the costs, or the safeguards.

That tension explains why this story reached far beyond a routine health update. For supporters, it is a sign of a leadership team trying to fix weakness and restore standards. For critics, it raises familiar worries about bureaucratic overreach, politicized medicine, and pressure on people in uniform who may not feel free to say no. The next major test will be whether the Pentagon publishes clear rules, clinical cutoffs, and a full rationale for the program.